nach oben

Canadian Journal of Anesthesia/Journal canadien d'anesthésie

Erschienen in:

10.07.2023 | Reports of Original Investigations

Effects of remimazolam on hemodynamic changes during cardiac ablation for atrial fibrillation under general anesthesia: a propensity-score-matched retrospective cohort study

verfasst von: Sun Woo Nam, MD, PhD, Subin Yim, MD, Chang Ik Choi, MD, Insun Park, MD, PhD, Kyoung-Woon Joung, MD, In-Ae Song, MD, PhD

Erschienen in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Abrupt hemodynamic changes or life-threatening arrhythmias are frequently observed in individuals receiving anesthesia for cardiac arrhythmia ablation. Remimazolam is a novel ultra-short-acting benzodiazepine that has been associated with better hemodynamic stability than conventional anesthetic agents do. This study aimed to investigate whether remimazolam reduces vasoactive agent use compared with desflurane in individuals undergoing ablation for atrial fibrillation under general anesthesia.

Methods

In a retrospective cohort study, we reviewed electronic medical records of adult patients who underwent ablation for atrial fibrillation under general anesthesia between July 2021 and July 2022. We divided patients into remimazolam and desflurane groups according to the principal agent used for anesthesia. The primary endpoint was the overall incidence of vasoactive agent use. We compared the groups using propensity-score matching (PSM) analysis.

Results

A total of 177 patients were included—78 in the remimazolam group and 99 in the desflurane group. After PSM, 78 final patients were included in each group. The overall incidence of vasoactive agent use was significantly lower in the remimazolam group than in the desflurane group (41% vs 74% before PSM; 41% vs 73% after PSM; both, P < 0.001). The incidence rate, duration, and maximum dose of continuous vasopressor infusion were also significantly lower in the remimazolam group (P < 0.001). Use of remimazolam was not associated with increased complications after the ablation procedures.

Conclusions

General anesthesia using remimazolam vs desflurane was associated with significantly reduced vasoactive agent requirement and better hemodynamic stability without increased postoperative complications in patients undergoing ablation for atrial fibrillation.

Nur mit Berechtigung zugänglich

Kim KM. Remimazolam: pharmacological characteristics and clinical applications in anesthesiology. Anesth Pain Med (Seoul) 2022; 17: 1–11. https://doi.org/10.17085/apm.21115

Goudra BG, Singh PM. Remimazolam: the future of its sedative potential. Saudi J Anaesth 2014; 8: 388–91. https://doi.org/10.4103/1658-354x.136627CrossRefPubMedPubMedCentral

Pastis NJ, Yarmus LB, Schippers F, et al. Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest 2019; 155: 137–46. https://doi.org/10.1016/j.chest.2018.09.015CrossRefPubMed

Liu T, Lai T, Chen J, et al. Effect of remimazolam induction on hemodynamics in patients undergoing valve replacement surgery: a randomized, double-blind, controlled trial. Pharmacol Res Perspect 2021; 9: e00851. https://doi.org/10.1002/prp2.851

Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020; 34: 543–53. https://doi.org/10.1007/s00540-020-02788-6CrossRefPubMed

Dada RS, Hayanga JWA, Woods K, et al. Anesthetic choice for atrial fibrillation ablation: a national anesthesia clinical outcomes registry analysis. J Cardiothorac Vasc Anesth 2021; 35: 2600–6. https://doi.org/10.1053/j.jvca.2020.12.046CrossRefPubMed

Martin CA, Curtain JP, Gajendragadkar PR, et al. Improved outcome and cost effectiveness in ablation of persistent atrial fibrillation under general anaesthetic. Europace 2018; 20: 935–42. https://doi.org/10.1093/europace/eux057CrossRefPubMed

Li KH, Sang T, Chan C, et al. Anaesthesia use in catheter ablation for atrial fibrillation: a systematic review and meta-analysis of observational studies. Heart Asia 2019; 11: e011155. https://doi.org/10.1136/heartasia-2018-011155

Malladi V, Naeini PS, Razavi M, Collard CD, Anton JM, Tolpin DA. Endovascular ablation of atrial fibrillation. Anesthesiology 2014; 120: 1513–9. https://doi.org/10.1097/aln.0000000000000261CrossRefPubMed

10.

Hamid A. Anesthesia for cardiac catheterization procedures. Heart Lung Vessel 2014; 6: 225–31.PubMedPubMedCentral

11.

von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–7. https://doi.org/10.1016/s0140-6736(07)61602-xCrossRef

12.

Jentzer JC, Vallabhajosyula S, Khanna AK, Chawla LS, Busse LW, Kashani KB. Management of refractory vasodilatory shock. Chest 2018; 154: 416–26. https://doi.org/10.1016/j.chest.2017.12.021CrossRefPubMed

13.

Hansen BB, Klopfer SO. Optimal full matching and related designs via network flows. J Comput Graph Stat 2006; 15: 609–27. https://doi.org/10.1198/106186006X137047CrossRef

14.

Hansen BB. Full matching in an observational study of coaching for the SAT. J Am Stat Assoc 2004; 99: 609–18. https://doi.org/10.1198/016214504000000647CrossRef

15.

Schüttler J, Eisenried A, Lerch M, Fechner J, Jeleazcov C, Ihmsen H. Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology 2020; 132: 636–51. https://doi.org/10.1097/aln.0000000000003103CrossRefPubMed

16.

Kleiman RB, Darpo B, Thorn M, Stoehr T, Schippers F. Potential strategy for assessing QT/QTc interval for drugs that produce rapid changes in heart rate: electrocardiographic assessment of the effects of intravenous remimazolam on cardiac repolarization. Br J Clin Pharmacol 2020; 86: 1600–9. https://doi.org/10.1111/bcp.14270CrossRefPubMedPubMedCentral

17.

Rex DK, Bhandari R, Desta T, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc 2018; 88: 427–37. https://doi.org/10.1016/j.gie.2018.04.2351CrossRefPubMed

18.

Rex DK, Bhandari R, Lorch DG, Meyers M, Schippers F, Bernstein D. Safety and efficacy of remimazolam in high risk colonoscopy: a randomized trial. Dig Liver Dis 2021; 53: 94–101. https://doi.org/10.1016/j.dld.2020.10.039CrossRefPubMed

19.

Chen SH, Yuan TM, Zhang J, et al. Remimazolam tosilate in upper gastrointestinal endoscopy: a multicenter, randomized, non-inferiority, phase III trial. J Gastroenterol Hepatol 2021; 36: 474–81. https://doi.org/10.1111/jgh.15188CrossRefPubMed

20.

Nakanishi T, Sento Y, Kamimura Y, Tsuji T, Kako E, Sobue K. Remimazolam for induction of anesthesia in elderly patients with severe aortic stenosis: a prospective, observational pilot study. BMC Anesthesiol 2021; 21: 306. https://doi.org/10.1186/s12871-021-01530-3CrossRefPubMedPubMedCentral

21.

Landoni G, Lomivorotov VV, Nigro Neto C, et al. Volatile anesthetics versus total intravenous anesthesia for cardiac surgery. N Engl J Med 2019; 380: 1214–25. https://doi.org/10.1056/nejmoa1816476CrossRefPubMed

22.

Kaushal RP, Vatal A, Pathak R. Effect of etomidate and propofol induction on hemodynamic and endocrine response in patients undergoing coronary artery bypass grafting/mitral valve and aortic valve replacement surgery on cardiopulmonary bypass. Ann Card Anaesth 2015; 18: 172–8. https://doi.org/10.4103/0971-9784.154470CrossRefPubMedPubMedCentral

23.

Hannam J, Mitchell S, Cumin D, et al. Haemodynamic profiles of etomidate vs propofol for induction of anaesthesia: a randomised controlled trial in patients undergoing cardiac surgery. Br J Anaesth 2019; 122: 198–205. https://doi.org/10.1016/j.bja.2018.09.027CrossRefPubMed

24.

Noseir RK, Ficke DJ, Kundu A, Arain SR, Ebert TJ. Sympathetic and vascular consequences from remifentanil in humans. Anesth Analg 2003; 96: 1645–50. https://doi.org/10.1213/01.ane.0000061587.13631.67CrossRefPubMed

25.

Sajedi P, Rahimian A, Khalili G. Comparative evaluation between two methods of induced hypotension with infusion of Remifentanil and Labetalol during sinus endoscopy. J Res Pharm Pract 2016; 5: 264–71. https://doi.org/10.4103/2279-042x.192463CrossRefPubMedPubMedCentral

26.

Schmidt M, Marschang H, Clifford S, et al. Trends in inflammatory biomarkers during atrial fibrillation ablation across different catheter ablation strategies. Int J Cardiol 2012; 158: 33–8. https://doi.org/10.1016/j.ijcard.2010.12.084CrossRefPubMed

27.

Huffman JC, Stern TA. The use of benzodiazepines in the treatment of chest pain: a review of the literature. J Emerg Med 2003; 25: 427–37. https://doi.org/10.1016/j.jemermed.2003.01.001CrossRefPubMed

28.

Dixon R, Edwards IR, Pilcher J. Diazepam in immediate post-myocardial infarct period. A double blind trial. Br Heart J 1980; 43: 535–40. https://doi.org/10.1136/hrt.43.5.535

29.

Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A Placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg 2012; 115: 284–96. https://doi.org/10.1213/ane.0b013e318241f68a

30.

Sheng XY, Liang Y, Yang XY, et al. Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers. Eur J Clin Pharmacol 2020; 76: 383–91. https://doi.org/10.1007/s00228-019-02800-3CrossRefPubMed

31.

Yamamoto T, Kurabe M, Kamiya Y. Re-sleeping after reversal of remimazolam by flumazenil. J Anesth 2021; 35: 322. https://doi.org/10.1007/s00540-021-02915-xCrossRefPubMed

32.

Penninga EI, Graudal N, Ladekarl MB, Jürgens G. Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication--a systematic review with meta-analyses of randomised trials. Basic Clin Pharmacol Toxicol 2016; 118: 37–44. https://doi.org/10.1111/bcpt.12434CrossRefPubMed

Titel: Effects of remimazolam on hemodynamic changes during cardiac ablation for atrial fibrillation under general anesthesia: a propensity-score-matched retrospective cohort study
verfasst von: Sun Woo Nam, MD, PhD
Subin Yim, MD
Chang Ik Choi, MD
Insun Park, MD, PhD
Kyoung-Woon Joung, MD
In-Ae Song, MD, PhD
Publikationsdatum: 10.07.2023
Verlag: Springer International Publishing
Erschienen in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie / Ausgabe 9/2023
Print ISSN: 0832-610X
Elektronische ISSN: 1496-8975
DOI: https://doi.org/10.1007/s12630-023-02514-2

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Effects of remimazolam on hemodynamic changes during cardiac ablation for atrial fibrillation under general anesthesia: a propensity-score-matched retrospective cohort study